Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03141671 · ClinicalTrials.gov registry record · Phase 2
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
A Phase 2 study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
- 8
- Study locations
NCT03141671: Active Phase 2 study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
NCT03141671 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 345 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (43% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03141671, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
- 8
- Study locations
Study Summary
This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Bicalutamide
- DRUG GnRH
- RADIATION Salvage radiation
Study Locations (8)
California
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago - Chicago
Massachusetts
- Dana-Farber Cancer Institute/Brigham and Women's Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2017-11-24 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03141671 still lists
NCT03141671 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Prednisone is the first listed.
NCT03141671 lists 8 locations in 7 states (California, Connecticut, Illinois).
Frequently Asked Questions
What is clinical trial NCT03141671 about?
NCT03141671 is a clinical study titled "Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)". This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).
What is the current status of trial NCT03141671?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2017-11-24. Estimated completion is 2025-12-31.
What conditions does trial NCT03141671 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03141671?
The interventions under investigation include: Prednisone (DRUG), Abiraterone (DRUG), Bicalutamide (DRUG), GnRH (DRUG), Salvage radiation (RADIATION).
Who is sponsoring clinical trial NCT03141671?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03141671 being conducted?
This trial has 8 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03141671's enrollment target sits among peer trials
345 150th of 735 higher than 586 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI